Clinical Issues in Chronic Liver DiseaseHot Topics in HBV, HCV, and NASH
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K, et al. J Hepatol. 2018;68(4):672-681.
Benedict M, Zhang X. World J Hepatol. 2017;9(16):715-732.
Byrne CD, Targher G. J Hepatol. 2015;62(suppl 1):S47-S64.
Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.
Cusi K, et al. Ann Intern Med. 2016;165(5):305-315.
Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis.
Dulai PS, et al. Hepatology. 2017;65(5):1557-1565.
Dyson JK, et al. J Clin Pathol. 2013;66(12):1033-1045.
Feld JJ, et al. N Engl J Med. 2014;370(17):1594-1603.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL, et al. Hepatology. 2018;67(5):1754-1767.
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, et al. Lancet Gastroenterol Hepatol. 2018;3(3):153-161.
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Hannah WN Jr, Harrison SA. Hepatology. 2016;64(6):2234-2243.
Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.
Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH, et al. Hepatology. 2013;58(2):546-554.
Lok AS, et al. Hepatology. 2017;66(4):1296-1313.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.
Loomba R, et al. Hepatology. 2018;67(2):549-559.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.
Improved bone and renal safety at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB).
Pan CQ, et al. Hepatology. 2017; 66(suppl 1):482A.
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
Papatheodoridis GV, et al. Hepatology. 2017;66(5):1444-1453.
Perazzo H, Dufour JF. Liver Int. 2017;37(5):634-647.
Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.
Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.
Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study.
Ratziu V, et al. J Hepatol. 2018;68(suppl 1):S1-S2.
Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.
Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Spengler EK, Loomba R. Mayo Clin Proc. 2015;90(9):1233-1246.
The performance of vibration controlled transient elastography in a US cohort of patients with non-alcoholic fatty liver disease.
Tapper EB, et al. Am J Gastroenterol. 2016;111(5):677-684.
Tapper EB, Loomba R. Nat Rev Gastroenterol Hepatol. 2018;15(5):274-282.
Testoni B, et al. Semin Liver Dis. 2017;37(3):231-242.
Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland.
Tyrfingsson T, et al. J Hepatol. 2018;68(suppl 1):S52
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
Wong VW, et al. Hepatology. 2010;51(2):454-462.
Global epidemiology of nonalcoholic fatty liver disease- Meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM, et al. Hepatology. 2016;64(1):73-84.
Hot Topics in HBV, HCV, and NASH
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
A Multidisciplinary Approach
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice